IRVING, Texas / Jul 24, 2023 / Business Wire / The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023.
“The dividend increase reflects confidence in our strategy and ability to generate sustained strong cash flows,” said Brian Tyler, chief executive officer. “We continue to remain disciplined in our approach to capital deployment and focused on driving sustainable growth while creating value for our shareholders.”
McKesson has increased its dividend for seven consecutive years.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
| Last Trade: | US$710.64 |
| Daily Change: | -8.09 -1.13 |
| Daily Volume: | 577,846 |
| Market Cap: | US$90.210B |
February 05, 2025 February 04, 2025 November 06, 2024 August 26, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
